tbuckley/cabot-search huggingface dataset:
Traité élémentaire d'exploration clinique médicale [technique et séméiologie]
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PANCREAS IN DIABETES.
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Low Back Pain
Authors: Adrian C. Traeger, Amir Qaseem, James H. McAuley
Journal: JAMA (2021)

James Heyward, MPH; Christopher M. Jones, PharmD, MPH; Wilson M. Compton, MD, MPE; Dora H. Lin, MHS; Jan L. Losby, PhD, MSW; Irene B. Murimi, PhD, MA; Grant T. Baldwin, PhD, MPH; Jeromie M. Ballreich, PhD, MHS; David A. Thomas, PhD; Mark C. Bicket, MD; Linda Porter, PhD; Jonothan C. Tierce, CPhil; G. Caleb Alexander, MD, MS
02.33 Altered bioenergetics, mitochondrial function and pro-inflammatory pathways in ra synovium in response to tofacitinib
Authors: Carl Orr, Trudy McGarry, Sarah Wade, Monika Biniecka, Siobhan Wade, Douglas Veale, Ursula Fearon
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background/purpose</h3> Rheumatoid arthritis (RA) is a chronic joint disease, characterised by synovial inflammation and destruction of articular cartilage/bone. The Janus-Kinase and Signal Transducer and Activator of Transcription (JAK-STAT) signalling pathway is implicated in the pathogenesis of RA. The objective of our research was to examine the effect of tofacitinib, a selective JAK inhibitor, on metabolic activity, mitochondrial function and pro-inflammatory mechanisms in RA. <h3>Methods</h3> Primary RA synovial fibroblasts (RASFC) and <i>ex-vivo</i> RA synovial explants were cultured with tofacitinib (1 µM) for 24–48 hours. RASFC metabolism was assessed by the XF24-Flux-analyser and RASFC mitochondrial mutagenesis was quantified using a mitochondrial random mutation capture assay (RMCA). Mitochondrial function was assessed for reactive oxygen species (ROS), mitochondrial membrane potential (MMP) and mitochondrial mass (MM) using the specific cell fluorescent probes and differential gene expression by mitochondrial gene arrays or RT-PCR. Lipid peroxidation (4HNE) was measured by specific ELISA. The effect of tofacitinib (1 µM) on RA pro-inflammatory mediators, including cytokines and growth factors were quantified by ELISA and MSD multiplex assays. <h3>Results</h3> During an initial screen, we observed alteration of 18 key genes involved in mitochondrial function in RA synovial tissue in response to tofacitinib. Supporting this, tofacitinib inhibited the production of ROS (p&lt;0.05), MMP (p&lt;0.06) and MM (p&lt;0.05) in RASFC with no effect observed for mitochondrial DNA-mutations or 4HNE. Tofacitinib significantly inhibited the expression of glycolytic genes HIF1α, HK2, GSK3A and PDK1 (all p&lt;0.05) suggesting altered energy metabolism. This was paralleled by a significant decreased baseline ECAR (glycolysis)(p&lt;0.05), with an observed simultaneous increase in baseline OCR (oxidative phosphorylation)(p&lt;0.05). In addition, tofacitinib increased ATP production, the maximal respiratory capacity and the respiratory reserve in RASFC (all p&lt;0.05). In RA whole tissue synovial explants, which maintain the architecture and cell-cell contact of the joint thus closely reflecting the <i>in-vivo</i> environment, tofacitinib significantly inhibited spontaneous secretion of IL-6, IL-8, IL-1b, ICAM-1, VEGF, Tie2 and MMP1 (all p&lt;0.05), confirming a bioenergetic switch in favour of resolution of inflammation. <h3>Conclusion</h3> This study demonstrates that tofacitinib inhibition of pro-inflammatory mechanisms is paralleled by metabolic reprogramming, and further supports JAK-STAT inhibition as a therapeutic target for the treatment of RA.
Nephron, Basel
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA
Authors: E. M. Scolnick
Journal: JAMA (1984)

A vaccine formulated from hepatitis B surface antigen (HBsAg) produced by a recombinant strain of the yeast<i>Saccharomyces cerevisiae</i>was administered to two groups of human volunteers composed of 37 healthy, low-risk adults. Each subject received a 10-μg dose of HBsAg at 0, 1, and 6 months. By one month, 27% to 40% of the vaccinees had antibody to HBsAg, and by three months 80% to 100% were antibody positive. Large boosts in titer followed the third dose at six months. The antibody formed is predominantly specific for the a determinant of HBsAg. There have been no serious reactions attributable to the vaccine. The most frequent complaint has been transient soreness at the injection site. As far as we know, this is the first reported use in man of a vaccine prepared by recombinant DNA technology. (<i>JAMA</i>1984;251:2812-2815)
Kurzes Handbuch der Ophthalmologie.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Percentage Equation
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
UNUSUAL INSTANCE OF FOREIGN BODY PENETRATING THE HEAD
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Squaring off over total parenteral nutrition
Authors: J. Elliott
Journal: JAMA (1980)

It is nearly 20 years since Stanley J. Dudrick, MD, now chairman of the Department of Surgery at the University of Texas Health Science Center at Houston, proposed that intravenous hyperalimentation (IVH) could improve the quality of life and the ability of some cancer patients to tolerate aggressive forms of chemotherapy. In that time, the debate over the technique (also referred to as total parenteral nutrition [TPN]) has periodically flared into controversy. Today there is no doubt that TPN can be a truly lifesaving treatment in some cancer patients. But does the technique actually lengthen survival times? Which patients will respond best to TPN, and which cancers will be most affected? Perhaps most important of all, does TPN improve a cancer patient's tolerance to therapy, as Dudrick first proposed in 1963? To all of these questions, and particularly the last, there are conflicting answers. The latest debate on TPN—which may
Bone Marrow May Be More Informative Than Peripheral Blood To Evaluate Minimal Residual Disease During 1st and 2nd Year Follow Up After First-Line Fludarabine, Cyclophosphamide, and Rituximab For Chronic Lymphocytic Leukemia
Authors: Paolo Strati, Michael J. Keating, Susan O'Brien, Jan A. Burger, Alessandra Ferrajoli, Nitin Jain, Zeev Estrov, Jeffrey L. Jorgensen, Stefan H. Faderl, William G. Wierda
Journal: Blood (2013)
Abstract 2975: Imipramine, an FDA approved anti-depressant, suppresses triple negative breast cancer growth and progression through inhibition of FOXM1 and DNA repair pathways
Authors: Santosh Timilsina, Subapriya Rajamanickam, Ismail Jatoi, Yidong Chen, Ratna Vadlamudi, Virginia Kaklamani, Manjeet K. Rao
Journal: Cancer Research (2020)

Abstract Triple Negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer that lacks effective targeted therapies with the main therapeutic option being cytotoxic chemotherapies, which have toxic side effects on patient's health. Less toxic alternatives that could target key pathways that are altered in TNBCs could lead to better outcomes for the patients. Important distinguishing traits of TNBCs is the high amounts of genomic instability and high number of alterations in key proteins in DNA repair and cell proliferation that helps the cancer grow, survive and progress. Previous findings from our lab indicate that Imipramine Blue, a derivative of anti-depressant imipramine, may be a potential inhibitor of proliferation and DNA repair pathways in TNBC. Therefore, we tested the therapeutic efficacy of Imipramine on TNBCs using various in vitro assays for viability, migration, invasion as well as in vivo xenograft assays for tumor growth. Our results demonstrate that Imipramine inhibits cancer cell viability and progression in vitro. Similarly, in vivo xenograft assays showed reduced tumor growth in pre-clinical models upon imipramine treatment. Importantly, at the molecular level, Imipramine treatment suppressed key players in both cell proliferation, and DNA repair pathways, including FOXM1; a proto-oncogene that is a master regulator of both cell proliferation and DNA Repair pathways. These findings suggest that Imipramine may be a potential therapeutic option for TNBC patients. A clinical trial is ongoing to test the efficacy of Imipramine in Triple Negative Breast Cancer patients. Citation Format: Santosh Timilsina, Subapriya Rajamanickam, Ismail Jatoi, Yidong Chen, Ratna Vadlamudi, Virginia Kaklamani, Manjeet K. Rao. Imipramine, an FDA approved anti-depressant, suppresses triple negative breast cancer growth and progression through inhibition of FOXM1 and DNA repair pathways [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2975.
化脓性汗腺炎中的成本节约
Authors: M. Argyropoulou, T. Kanni, M. Kyprianou, N. Melachroinopoulos, E.J. Giamarellos‐Bourboulis
Journal: British Journal of Dermatology (2019)

化脓性汗腺炎(HS)是一种常见的皮肤病,欧洲近 1% 的人口受其困扰。HS 使存在汗腺的皮肤(如腋窝、乳房、腹股沟和臀部)形成脓肿。该病以周期性为特征,在一个周期中,症状加重,脓疱逐渐增大并破裂,产生脓血。这项在希腊雅典 ATTIKON 大学医院进行的研究重点关注了阻滞肿瘤坏死因子蛋白的药物(此后称为抗‐TNF 药物)对于 HS 的治疗疗效。一种抗‐TNF 化合物阿达木单抗在 2015 年获准用于中重度 HS。作者们分析了 250 例接受长期随访的中重度 HS 患者,他们调查了抗‐TNF 药物对于防止 HS 恶化(症状加重)和 HS 治疗成本的影响。作者们发现抗‐TNF 药物治疗使恶化频率下降 38%;在中和重度 HS 中均是如此。作者们计算了单独接受其他治疗和单独接受抗‐TNF 药物治疗患者的‐访视支出。在减去各次注射的成本后,作者们发现通过抗‐TNF 药物实现的成本节约为 178.92 欧元/次访视。在其他治疗下,最严重患者的平均年度支出为 8309.6 欧元,在抗‐TNF 药物治疗下时为 3262.2 欧元。这些支出结果是针对阿达木单抗的,将此药物的支出用于计算。因此,这项研究的结果显示,阿达木单抗可能是一种对于 HS 具有成本效益且高效的治疗。
Error in Affiliation
Authors: Anca Radulescu, Nadia Radu, Alexandra Preda, Carmen Iuga, Mariana Dinu, Iuliana Dobre, Florin Tibu, Bogdan Simon, Mark Wade
Journal: JAMA Psychiatry (2019)

Efficacy and Posttreatment Effects of Cognitive Behavioral Therapy vs Supportive Psychotherapy for Body Dysmorphic Disorder
Two Health Seekers in Southern California.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Traumatic displacement of fat.
Journal: BMJ (1972)

in younger patients, though it must be recognized that fre- quently this may require a bilateral block dissection, since many of these tumours metastasize to both sides of the neck.One of the common causes of death is recurrence in the cer- vical region, and E. W. Strong and colleagues" have shown that the rate can be reduced by giving low doses of irradiation before operation.In a controlled trial they found re- duction of cervical recurrence rates from 50% to 31 % when this was done. 1
Retraction: Article on Inhibition of Carcinogenesis in Rat Mammary Glands
Journal: Cancer Research (2005)

After a thorough investigation by the institution where the research originated, it has been determined that key data in the article by Badawi and associates (1) in the February 1, 2004, issue of Cancer Research were fabricated. No supporting laboratory evidence could be found for the data and thus the conclusions of the article are in question.The lead authors of the article and the coauthors have not responded to several inquiries. The sponsoring institution and the publishers of Cancer Research agree that the article should be retracted from the literature.
Letter: Lincomycin and clindamycin colitis.
Authors: E Field, H Jenssen, H Kohler, J Gu4nther, H Meyer-Rienecker
Journal: BMJ (1974)

exposed to antigens of banal viruses such as influenza.'6 Macrophages from animals so sensitized constitute a faulty indicator sys- tem for human lymphocyte-P.P.D. interac- tion.We have, however, found that even with guinea-pigs which have not been rigorously shielded from "spontaneous" sensi- tization and so show clear evidence of sensi- tivity to E.F. and P.P.D. it is still possible to obtain positive results in the L.A.D. test if thyroid is used as test antigen for the human lymphocytes instead of P.P.D. In- deed, if the same M.S. lymphocytes are tested with both thyroid and P.P.D., then the high result characteristic of the disease is obtained with thyroid but not with P.P.D. Results with the latter seem to be randomly distributed depending upon a number of factors not as yet studied.Two examples from our protocols are set out in the table.It will be seen that when an animal which is not presensitized to E.F. and P.P.D. is used as the source of indicator macrophages the customary high result is found with both P.P.D. and thyroid.When, however, a pre- sensitized guinea-pig is used for the macro- phages then the high result is obtained only with the unrelated thyroid antigen.'All these experiments were carried out with the ori- ginal macrophage electrophoretic mobility (M.E.M.) test.2The importance of these results is that they (1) underline the need for the use of guinea-pigs free from "spontaneous" sensi- tization, (2) show that it is possible for those who do not have access to a protected source of anmials to carry out M.S. testing with thyroid antigen, and (3) explain the difficul- ties experienced by Foster et al. in their work with P.
Book Listings
Journal: Annals of Internal Medicine (2001)

Book Listings20 February 2001Book ListingsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-4-200102200-00002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail CardiologyBasic Electrocardiography in Ten DaysDR Ferry. 266 pages. New York: McGraw-Hill; 2001. $40.00. ISBN 0071352929. Order phone 800-262-4729.Cardiac Pacing and Defibrillation: A Clinical ApproachDL Hayes, MA Lloyd, and PA Friedman. 600 pages. Armonk, NY: Futura; 2000. $89.00. ISBN 087993462X. Order phone 800-877-8761.Cardiovascular Medicine2nd edition. JT Willerson and JN Cohn, eds. 2344 pages. Philadelphia: WB Saunders; 2000. $165.00. ISBN 0443070008. Order phone 800-545-2522.Dispersion of Ventricular Repolarization: State of the ArtSB Olsson, JP Amlie, and S Yuan, eds. 330 pages. Armonk, NY: Futura; 2000. $125.00. ISBN 0879934581. Order phone 800-877-8761.Handbook of Contrast Echocardiography: Left Ventricular Function and ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 February 2001Volume 134, Issue 4Page: B1KeywordsBurnsHealth information technologyPrevention, policy, and public health ePublished: 20 February 2001 Issue Published: 20 February 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...